[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Numerous genetic mutations have been identified in the DPD gene locus (DPYD), with a few variants having functional consequences on enzymatic activity. The allele frequency is 5% for heterozygoty and is 0.2% for homozygoty. It is correlated to the frequency of DPD activity deficiency that has been frequently reported to cause early severe, sometimes lethal fluoropyrimidine-related adverse events, regardless of the drug. Taking in account the wide and frequent use of fluoropyrimidines, both in advanced and adjuvant settings, it is clearly a problem of public healthcare that cannot be underestimated. We review in the present article the performances of assays that assess DPD and DPYD status, with an emphasis on their respective robustness and suitability for routine clinical applications. We show that DPD deficiency can be already detected primarily to treatment in practice and this detection could avoid life-threatening fluoropyrimidines toxic-side effects.
Département de biopathologie du cancer, Centre régional de lutte contre le cancer Paul Papin, CRCNA Inserm U892, Angers. m.boisdron@unimedia.fr
M
M
Boisdron-Celle
A
A
Morel
E
E
Gamelin
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D054067:Dihydropyrimidine Dehydrogenase Deficiency / Q000150:complications*; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011743:Pyrimidines / Q000009:adverse effects*
D000964:Antimetabolites, Antineoplastic; D011743:Pyrimidines; D042943:Dihydrouracil Dehydrogenase (NADP)